Thanks Twinter, but aren't we at this stage now? Haven't the 5 patients in our TNBC study lived well beyond what was expected, and haven't we already (and immediately) showed a 90% reduction (700 mg) in circulating tumor DNA in Clover?
Oh, and about those pesky side effects:
"Common side effects of Etcamah include visual disturbances, bradycardia, neutropenia, infections, diarrhoea, nausea, anaemia, fatigue, and leukopenia.
Common Side Effects
Etcamah, when used in combination with a CDK4/6 inhibitor, may cause several side effects. The most frequently reported include neutropenia (low white blood cell count), visual effects such as photopsia (flashes of light), infections, diarrhoea, nausea, anaemia (low red blood cell count), fatigue, bradycardia (slow heart rate), and leukopenia (low white blood cell count) (EMA, 2026)
ema.europa.eu
ema.europa.eu
+2
. Among these, visual disturbances and bradycardia are specifically associated with Etcamah itself rather than the CDK4/6 inhibitor (EMA, 2026)
ema.europa.eu
ema.europa.eu
.
Serious Side Effects
Some side effects can be serious, including infections and fever, which may affect up to 1 in 10 patients. Bradycardia and QTc prolongation have also been reported, and in rare cases, a non-fatal Torsades de Pointes occurred in a patient receiving Etcamah with ribociclib, highlighting the need for careful cardiac monitoring (EMA, 2026)
ema.europa.eu
ema.europa.eu
. Patients with pre-existing heart conditions or those taking other QTc-prolonging drugs should exercise caution.
Visual and Neurological Effects
Visual side effects may include blurred vision, diplopia, photophobia, and visual perseveration, and are generally transient. These effects may slightly affect activities such as driving or operating machinery, but are usually minor (RxReasoner, 2026)
rxreasoner.com
rxreasoner.com
.
Fertility: Animal studies indicate potential effects on male and female reproductive organs and fertility (RxReasoner, 2026)"
Simple question: If Etcamah received accelerated approval, why not Leronlimab?
Oh, and about those pesky side effects:
"Common side effects of Etcamah include visual disturbances, bradycardia, neutropenia, infections, diarrhoea, nausea, anaemia, fatigue, and leukopenia.
Common Side Effects
Etcamah, when used in combination with a CDK4/6 inhibitor, may cause several side effects. The most frequently reported include neutropenia (low white blood cell count), visual effects such as photopsia (flashes of light), infections, diarrhoea, nausea, anaemia (low red blood cell count), fatigue, bradycardia (slow heart rate), and leukopenia (low white blood cell count) (EMA, 2026)
ema.europa.eu
ema.europa.eu
+2
. Among these, visual disturbances and bradycardia are specifically associated with Etcamah itself rather than the CDK4/6 inhibitor (EMA, 2026)
ema.europa.eu
ema.europa.eu
.
Serious Side Effects
Some side effects can be serious, including infections and fever, which may affect up to 1 in 10 patients. Bradycardia and QTc prolongation have also been reported, and in rare cases, a non-fatal Torsades de Pointes occurred in a patient receiving Etcamah with ribociclib, highlighting the need for careful cardiac monitoring (EMA, 2026)
ema.europa.eu
ema.europa.eu
. Patients with pre-existing heart conditions or those taking other QTc-prolonging drugs should exercise caution.
Visual and Neurological Effects
Visual side effects may include blurred vision, diplopia, photophobia, and visual perseveration, and are generally transient. These effects may slightly affect activities such as driving or operating machinery, but are usually minor (RxReasoner, 2026)
rxreasoner.com
rxreasoner.com
.
Fertility: Animal studies indicate potential effects on male and female reproductive organs and fertility (RxReasoner, 2026)"
Simple question: If Etcamah received accelerated approval, why not Leronlimab?
4
